Merus Announces $55.8 Million Private Placement Offering of Common Stock

Merus (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), announced that it has agreed to sell 3.1 million shares of its common shares to Biotechnology Value Fund, L.P. and certain of its affiliates (BVF), Aquilo Capital Management (Aquilo), Sofinnova Venture Partners L.P., and LSP Life Sciences Fund NV in a private placement.

As quoted in the press release:

Mark Lampert, President of BVF, and Marc Schneidman, Chief Investment Officer of Aquilo, stated, “BVF and Aquilo believe strongly in the fundamental value of Merus and the Biclonics® technology. We are privileged to make this investment in the Company and value the opportunity to provide additional leverage to the clinical development of very promising drug candidates that we believe will yield meaningful clinical data in the near future.”

Click here to read the full press release.